Inmed Pharmaceuticals Inc (INM)

$2.29 +0.03 (1.33%)
Market Cap 5.46M
Revenue (ttm) 4.94M
Net Income (ttm) -8.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -165.18%
Debt to Equity Ratio 0.00
Volume 55,000
Avg Vol 67,792
Day's Range N/A - N/A
Shares Out 2.38M
Stochastic %K 63%
Beta 0.30
Analysts Strong Buy
Price Target $45.00

Company Profile

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its pres...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 604 669 7207
Fax: 778 945 6800
Address:
885 West Georgia Street, Suite 1445, Vancouver, Canada
Space0
Space0 Oct. 2 at 3:44 PM
$INM any updates?
0 · Reply
taneraydar
taneraydar Sep. 29 at 11:10 PM
$INM watching closely
0 · Reply
kshonstocks
kshonstocks Sep. 29 at 2:52 PM
$INM 50 dma b/o pattern
0 · Reply
Space0
Space0 Sep. 29 at 2:23 PM
$INM something good here 👀
0 · Reply
PrimeTradingCorp
PrimeTradingCorp Sep. 29 at 12:54 AM
$PAVS pivot strength! $1.15 post-market, MACD histogram up, volume tease. $2.50 target locked! $DOGE.X Back up, LFG! $PWM Keep going this week $ZEO Those were good dip buys $INM Still watching, seems stuck
0 · Reply
STAFWINS
STAFWINS Sep. 26 at 1:59 PM
$BIAF Congrats on this one. Next runners: $APVO $ALLR $INM $ARMP
0 · Reply
SPYmyQQQ
SPYmyQQQ Sep. 25 at 12:03 PM
🚀 New Signal ✅ 💊 $INM 🗓️ Sep 25, 2025 💵 Entry: $2.18 🎯 Target (Opt.): $2.59 (+18.81%) 👉 Check bio for full access
0 · Reply
ChartChartist
ChartChartist Sep. 23 at 5:55 PM
$INM what a shtt
0 · Reply
Bulltrader988
Bulltrader988 Sep. 23 at 12:42 PM
$INM 👃👀 https://www.stocktitan.net/news/INM/in-med-pharmaceuticals-reports-full-year-fiscal-2025-financial-i8iezicupgy4.html
0 · Reply
newsfile_corp
newsfile_corp Sep. 23 at 12:30 PM
https://nfne.ws/267483 $INM @inmedpharma #cannabinoids #inm #inmed #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Ear
0 · Reply
Latest News on INM
InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

Sep 23, 2025, 8:30 AM EDT - 11 days ago

InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

Sep 16, 2025, 1:39 PM EDT - 18 days ago

InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 1:33 PM EDT - 4 weeks ago

InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025

Jul 28, 2025, 7:00 AM EDT - 2 months ago

InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Jun 27, 2025, 7:00 AM EDT - 3 months ago

InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Jun 25, 2025, 8:00 AM EDT - 3 months ago

InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

Jun 24, 2025, 7:00 AM EDT - 3 months ago

InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

Jun 13, 2025, 4:30 PM EDT - 4 months ago

InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

May 12, 2025, 6:00 PM EDT - 5 months ago

InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 12, 2025, 6:54 PM EST - 8 months ago

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

Feb 3, 2025, 7:30 AM EST - 8 months ago

InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

Jan 22, 2025, 7:30 AM EST - 9 months ago

InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

Jan 21, 2025, 7:30 AM EST - 9 months ago

InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

InMed Announces Results of 2024 Annual General Meeting

Dec 18, 2024, 8:00 PM EST - 10 months ago

InMed Announces Results of 2024 Annual General Meeting

InMed Enters Into Standby Equity Purchase Agreement

Dec 17, 2024, 4:56 PM EST - 10 months ago

InMed Enters Into Standby Equity Purchase Agreement

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

Nov 19, 2024, 7:30 AM EST - 11 months ago

InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

Nov 14, 2024, 4:45 PM EST - 11 months ago

InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

Nov 8, 2024, 4:44 PM EST - 11 months ago

InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

Nov 5, 2024, 8:30 AM EST - 11 months ago

InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

Oct 28, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

Oct 24, 2024, 8:00 AM EDT - 1 year ago

InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

Oct 22, 2024, 8:00 AM EDT - 1 year ago

InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

Sep 30, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

Sep 20, 2024, 4:30 PM EDT - 1 year ago

InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

Aug 21, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents

InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday

Aug 20, 2024, 10:10 AM EDT - 1 year ago

InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

Aug 20, 2024, 7:30 AM EDT - 1 year ago

InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

Jul 30, 2024, 8:00 AM EDT - 1 year ago

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data

InMed to Present at the Emerging Growth Conference

Jun 10, 2024, 5:18 PM EDT - 1 year ago

InMed to Present at the Emerging Growth Conference

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

May 14, 2024, 8:30 AM EDT - 1 year ago

InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

Apr 18, 2024, 8:00 AM EDT - 1 year ago

InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

Apr 16, 2024, 8:00 AM EDT - 1 year ago

InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

Apr 4, 2024, 8:00 AM EDT - 1 year ago

InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

Mar 20, 2024, 8:30 AM EDT - 1 year ago

InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

Feb 13, 2024, 5:41 PM EST - 1 year ago

InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

Feb 9, 2024, 8:00 AM EST - 1 year ago

InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

Jan 18, 2024, 4:41 PM EST - 1 year ago

InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

Jan 16, 2024, 8:00 AM EST - 1 year ago

InMed Pharmaceuticals Provides Business Update and Milestones for 2024

InMed Announces Results of 2023 Annual General Meeting

Dec 19, 2023, 6:03 PM EST - 1 year ago

InMed Announces Results of 2023 Annual General Meeting

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

Nov 14, 2023, 8:04 AM EST - 2 years ago

InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

Nov 2, 2023, 8:00 AM EDT - 2 years ago

InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

Oct 26, 2023, 7:15 PM EDT - 2 years ago

InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

Oct 24, 2023, 4:38 PM EDT - 2 years ago

InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules

InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies

Oct 24, 2023, 7:30 AM EDT - 2 years ago

InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies

InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update

Sep 29, 2023, 1:21 PM EDT - 2 years ago

InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

Sep 22, 2023, 6:15 PM EDT - 2 years ago

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

Sep 7, 2023, 8:30 AM EDT - 2 years ago

InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference

InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET

Jul 21, 2023, 7:30 AM EDT - 2 years ago

InMed to Participate in Fireside Chat with Water Tower Research on July 25, 2023 at 2pm ET

InMed Provides Update on BayMedica Rare Cannabinoid Business

Jul 20, 2023, 7:30 AM EDT - 2 years ago

InMed Provides Update on BayMedica Rare Cannabinoid Business

InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa

Jun 22, 2023, 7:30 AM EDT - 2 years ago

InMed Pharmaceuticals Inc. Announces Results from a Phase 2 Clinical Trial in Epidermolysis Bullosa

Space0
Space0 Oct. 2 at 3:44 PM
$INM any updates?
0 · Reply
taneraydar
taneraydar Sep. 29 at 11:10 PM
$INM watching closely
0 · Reply
kshonstocks
kshonstocks Sep. 29 at 2:52 PM
$INM 50 dma b/o pattern
0 · Reply
Space0
Space0 Sep. 29 at 2:23 PM
$INM something good here 👀
0 · Reply
PrimeTradingCorp
PrimeTradingCorp Sep. 29 at 12:54 AM
$PAVS pivot strength! $1.15 post-market, MACD histogram up, volume tease. $2.50 target locked! $DOGE.X Back up, LFG! $PWM Keep going this week $ZEO Those were good dip buys $INM Still watching, seems stuck
0 · Reply
STAFWINS
STAFWINS Sep. 26 at 1:59 PM
$BIAF Congrats on this one. Next runners: $APVO $ALLR $INM $ARMP
0 · Reply
SPYmyQQQ
SPYmyQQQ Sep. 25 at 12:03 PM
🚀 New Signal ✅ 💊 $INM 🗓️ Sep 25, 2025 💵 Entry: $2.18 🎯 Target (Opt.): $2.59 (+18.81%) 👉 Check bio for full access
0 · Reply
ChartChartist
ChartChartist Sep. 23 at 5:55 PM
$INM what a shtt
0 · Reply
Bulltrader988
Bulltrader988 Sep. 23 at 12:42 PM
$INM 👃👀 https://www.stocktitan.net/news/INM/in-med-pharmaceuticals-reports-full-year-fiscal-2025-financial-i8iezicupgy4.html
0 · Reply
newsfile_corp
newsfile_corp Sep. 23 at 12:30 PM
https://nfne.ws/267483 $INM @inmedpharma #cannabinoids #inm #inmed #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Ear
0 · Reply
STAFWINS
STAFWINS Sep. 22 at 1:58 PM
$ALLR Let's go $APVO $BTBT $ARMP $INM
0 · Reply
Bulltrader988
Bulltrader988 Sep. 21 at 9:30 PM
$INM Corporate presentation was updated this month 👃👀 https://www.inmedpharma.com/wp-content/uploads/2023/02/InMed-Corp-Deck_September-2025.pdf
0 · Reply
StockHounding
StockHounding Sep. 21 at 9:00 PM
$ARBB $INM $PAVS $SPAI Good seeing you on PAVS squeeze
0 · Reply
SqueezeMagnet
SqueezeMagnet Sep. 21 at 8:48 PM
$PAVS on Watch for a move . .85 to 1.15 + $SPAI hot $ARBB squeezed $INM could go
0 · Reply
STAFWINS
STAFWINS Sep. 19 at 12:46 PM
$APVO Winners next week $ALLR $SHPH $INM $ARMP
0 · Reply
BullseyeStock
BullseyeStock Sep. 19 at 4:14 AM
$MGIH $SNTG $SOHO $INM VRME is setting up perfectly for a moonshot. This ticker is known to run massive. Solid DD to back up its rally, right now not many folks knows about this gem, so be early bulls.
0 · Reply
SqueezeMagnet
SqueezeMagnet Sep. 18 at 2:40 PM
$INM Data presentation at 2PM today .. one to watch ! 😇🧤 $PAVS Zero borrow Squeeze play . 😇🧤 $BREA was fire ! $SQQQ Grabbed some $15.66 .. sl same price
0 · Reply
SqueezeMagnet
SqueezeMagnet Sep. 17 at 5:11 PM
$INM might squeeze on Data Presentation tomorrow .. one to watch
1 · Reply
aw20
aw20 Sep. 17 at 5:10 PM
$INM it's starting 👀
0 · Reply
SqueezeMagnet
SqueezeMagnet Sep. 17 at 5:07 PM
$INM Squeezy?
0 · Reply
aw20
aw20 Sep. 16 at 7:38 PM
$INM let's go 👀 now drop the news
0 · Reply
Bulltrader988
Bulltrader988 Sep. 16 at 6:49 PM
$INM ....👃👀
0 · Reply